Pharmatest Services

Pharmatest Services is a CRO that specializes in providing preclinical efficacy services in the therapeutic areas of oncology and skeletal diseases. Founded in 1998 and headquartered in Finland, Pharmatest is a preclinical contract research organization that offers translational research services for diseases with unmet clinical needs. The company's full-service research solutions for early drug development cover in vitro cell culture assays, in vivo models, model and assay development services, and more. Pharmatest's range of services aims to establish the proof-of-efficacy of cancer drug candidates through predictive cell culture assays, organotypic 3D models, and animal models. Additionally, it offers clinically predictive bone cell culture assays and animal models for skeletal diseases such as osteoporosis and osteoarthritis, supporting bone safety testing for drug development. The company's mission is to reduce the failure rate of drug candidates in clinical trials by making nonclinical drug development faster and more predictive. These services have attracted Private Equity Round investment from Aboa Venture Management in January 2014. Pharmatest's commitment to accelerating drug development while reducing costs positions it as a valuable player in the Biotechnology and Pharmaceutical industries.